Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors
Source abstract
Abstract
Background: advanced ovarian cancer often presents with ascites. These ascites contain small clusters of cancer cells, which may contribute greatly to the metastatic potential of ovarian cancer in the peritoneal cavity. Therefore, understanding the unique protein expressions of this cell population will provide vital information for the development of tailored, targeted treatment. In this study, we isolate floating ovarian cancer cells from ovarian cancer patient ascitic fluid and use these cells to document that the expression of EGFR/HER-2 proteins may be essential for the growth and survival of these floating cancer cell clusters. Methods: ascitic fluid-derived cells were isolated from ascitic fluid by using Ficoll separation. Cells were cultured in a non-adherent condition for six days. The protein level of EGFR, HER-2, AKT, and ERK and their phosphorylation in ovarian cancer cell lines were determined by immunofluorescence. The immunofluorescent staining for proteins presented in ascitic fluid-derived cells determined the intensity profile of each protein using Carl Zeiss Blue software. Results: Isolated ovarian cancer cells from ascitic fluid have a measurable level of EGFR and HER-2 proteins. The inhibition of EGFR and EGFR/HER-2 positive cells with gefitinib and canertinib selectively disrupts cell viability and the protein level of EGFR, HER-2, AKT and ERK and their respective phosphorylation status. In addition, the dual EGFR/HER-2 inhibitor canertinib demonstrates greater anti-tumour effects than gefitinib in EGFR/HER-2 positive cells. Conclusion: These studies reveal an important role of multiple activation of receptor tyrosine kinases in floating ovarian cancer cells, as well as the importance of a dual EGFR/HER-2 inhibitor used as alternative adjuvant therapy in advanced ovarian cancer patients.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: HER2/EGFR in Cancer Research · Monoclonal and Polyclonal Antibodies Research · Cancer Cells and Metastasis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Gynaecological Cancer Research Group, Department of Obstetrics and Gynaecology, University of Otago, Christchurch 8140, New Zealand
Funding
Ovarian Cancer Research Foundation
References (51)
Show source-provided references
1. Pattern and prognostic factors in patients with malignant ascites: A retrospective study10.1093/annonc/mdl499 ↗
2. Disease confined within the ovary and smaller amount of ascites are good prognostic factors for survival of patients with squamous cell carcinoma arising from mature cystic teratoma of the ovary: A case series in Korea and review of the published reports10.1111/j.1447-0756.2008.00841.x ↗
3. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study10.1016/j.ygyno.2015.07.103 ↗
4. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer10.1111/cas.12987 ↗
5. Trachana, S., Pilalis, E., Gavalas, N.G., Tzannis, K., Papadodima, O., Liontos, M., Rodolakis, A., Vlachos, G., Thomakos, N., and Haidopoulos, D. (2016). The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. PLoS ONE, 11.10.1371/journal.pone.0156403 ↗
6. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells10.3389/fimmu.2017.01482 ↗
7. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer10.3389/fonc.2017.00024 ↗
8. Disaggregation and invasion of ovarian carcinoma ascites spheroids10.1186/1479-5876-4-6 ↗
9. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients10.1038/nprot.2006.328 ↗
10. Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance10.4161/cc.8.1.7533 ↗
11. Stem and Progenitor-Like Cells Contribute to the Aggressive Behavior of Human Epithelial Ovarian Cancer10.1158/0008-5472.CAN-04-3931 ↗
12. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells10.1093/jnci/93.18.1375 ↗
13. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
14. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors
15. EGFR mutations and EGFR tyrosine kinase inhibitor in non-small cell lung cancer10.1016/j.soncn.2007.11.009 ↗
16. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: Optimising EGFR-targeted treatment options10.1038/sj.bjc.6603847 ↗
17. Tyrosine kinase signalling in breast cancer Epidermal growth factor receptor: Convergence point for signal integration and diversification10.1186/bcr52 ↗
18. A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models10.1007/s40487-016-0031-1 ↗
19. Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells10.1016/j.canlet.2018.02.013 ↗
20. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling10.18632/oncotarget.4996 ↗
21. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer10.1080/13543784.2017.1299707 ↗
22. Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer10.1016/j.celrep.2017.03.015 ↗
23. Proteomic Analysis ofMalignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling10.1158/1078-0432.CCR-05-2516 ↗
24. Rosso, M., Majem, B., Devis, L., Lapyckyj, L., Besso, M.J., Llaurado, M., Abascal, M.F., Matos, M.L., Lanau, L., and Castellví, J. (2017). E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS ONE, 12.10.1371/journal.pone.0184439 ↗
25. Latifi, A., Luwor, R.B., Bilandzic, M., Nazaretian, S., Stenvers, K., Pyman, J., Zhu, H., Thompson, E.W., Quinn, M.A., and Findlay, J.K. (2012). Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors. PLoS ONE, 7.10.1371/journal.pone.0046858 ↗
26. Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells10.1038/onc.2014.264 ↗
27. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma10.1186/1423-0127-19-23 ↗
28. Ó Donnell, R.L., McCormick, A., Mukhopadhyay, A., Woodhouse, L.C., Moat, M., Grundy, A., Dixon, M., Kaufman, A., Soohoo, S., and Elattar, A. (2014). The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis. PLoS ONE, 9.10.1371/journal.pone.0090604 ↗
29. Strauss, R., Li, Z., Liu, Y., Beyer, I., Persson, J., Sova, P., Möller, T., Pesonen, S., Hemminki, A., and Hamerlik, P. (2011). Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity. PLoS ONE, 6.10.1371/annotation/8c637352-3614-406c-89dc-e78d10fa069c ↗
30. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype10.1002/ijc.24188 ↗
31. Putative stem cells and epithelialmesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers10.1186/s13048-017-0306-7 ↗
32. The ErbB signalling pathway: Protein expression and prognostic value in epithelial ovarian cancer10.1038/sj.bjc.6604471 ↗
33. Lanitis, E., Dangaj, D., Hagemann, I.S., Song, D.-G., Best, A., Sandaltzopoulos, R., Coukos, G., and Powell, D.J. (2012). Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels. PLoS ONE, 7.10.1371/journal.pone.0049829 ↗
34. Epithelial growth factor receptor status in primary and recurrent ovarian cancer10.1038/modpathol.3800575 ↗
35. Vermeij, J., Teugels, E., Bourgain, C., Xiangming, J., in’t Veld, P., Ghislain, V., Neyns, B., and De Greve, J. (2008). Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer, 8.10.1186/1471-2407-8-3 ↗
36. Tuefferd, M., Couturier, J., Penault-Llorca, F., Vincent-Salomon, A., Broë, P., Guastalla, J., Allouache, D., Combe, M., Weber, B., and Pujade-Lauraine, E. (2007). HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients. PLoS ONE, 2.10.1371/journal.pone.0001138 ↗
37. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cance10.1007/s12032-014-0391-z ↗
38. Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)10.1634/theoncologist.10-8-579 ↗
39. A Phase II Evaluation of Gefitinib in the Treatment of Persistent or Recurrent Endometrial Cancer: A Gynecologic Oncology Group Study10.1016/j.ygyno.2013.02.019 ↗
40. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer10.1002/cncr.22545 ↗
41. Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial10.1200/JCO.2012.45.4272 ↗
42. A Phase II Study of Gefitinib in Patients with Metastatic Melanoma10.1097/CMR.0b013e3283471073 ↗
43. Signaling of ERBB Receptor Tyrosine Kinases Promotes Neuroblastoma Growth in vitro and in vivo10.1002/cncr.25073 ↗
44. Irwin, M.E., Nelson, L.D., Santiago-O’Farrill, J.M., Knouse, P.D., Miller, C.P., Palla, S.L., Siwak, D.R., Mills, G.B., Estrov, Z., and Li, S. (2013). Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. PLoS ONE, 8.10.1371/journal.pone.0070608 ↗
45. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-103310.4161/cbt.7.12.6942 ↗
46. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models10.1038/onc.2008.109 ↗
47. Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study10.1158/1078-0432.CCR-04-1187 ↗
48. Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patientswith Refractory Cancer10.1158/1078-0432.CCR-06-1958 ↗
49. Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer10.1200/JCO.2005.08.091 ↗
50. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability10.1093/carcin/bgu049 ↗
51. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy10.1007/s11523-015-0369-6 ↗